Skip to main content

Table 5 Logistic regression analysis of variables associated with neutropenia

From: GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients

Variables Unadjusted values Adjusted values
P value OR (95% CI) P value Adjusted OR (95% CI)
Age (≤ 50/ > 50) 0.163 0.515 (0.202–1.309) 0.127 0.252 (0.043–1.483)
Menopause (no/yes) 0.733 0.853 (0.341–2.131) 0.324 2.446 (0.414–14.440)
T-stage (T3-T4/T0-T2) 0.965 1.020 (0.413–2.520) 0.593 1.316 (0.481–3.597)
N-stage (N2-N3/N0-N1) 0.313 0.578 (0.199–1.678) 0.320 0.553 (0.172–1.776)
Clinical stage (IV/I–III) 0.911 1.064 (0.360–3.142) 0.860 1.113 (0.340–3.637)
Molecular subtype (TNBC/non-TNBC) 0.817 1.168 (0.313–4.367) 0.450 1.747 (0.410–7.442)
Chemotherapy regimen/dose ((docetaxel 75 mg/m2 and epirubicin 75 mg/m2)/(docetaxel 90 mg/m2 and epirubicin 90 mg/m2)) 0.197 2.014 (0.695–5.835) 0.124 2.454 (0.782–7.697)
GSTP1 c.313A > G (A/G + G/G vs. A/A) 0.031 4.038 (1.132–14.395) 0.031 4.273 (1.141–16.000)
  1. TNBC Triple-negative breast cancer